<DOC>
	<DOCNO>NCT00576238</DOCNO>
	<brief_summary>Topical steroid cream well moisturize cream important part treatment strategy atopic eczema . This study aim investigate tolerance new strong steroid cream comparison already market reference cream equal amount active different cream vehicle . The second part study investigate possible preventative property moisturize cream skin previously clear eczema .</brief_summary>
	<brief_title>Skin Tolerance Study Betamethasone Creams Atopic Eczema Preventative Properties Moisturiser</brief_title>
	<detailed_description />
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>Females male 18 65 year age Caucasian AD accord criterion Hanifin Rajka ( 12 ) eczematous lesion correspond Atopic Dermatitis Severity Index ( ADSI ) ( 13 ) score least 6 follow area : arm , leg , chest , abdomen back No serious health condition may interfere study Written informed consent Eczematous region exclusively intertriginous area face Use topical steroid dermatologic drug therapy ( moisturise cream allow ) study area light therapy within precede 2 week Use oral steroid within 1 month prior study Use concurrent medication e.g . medication may interfere study related activity Factors suggest low compliance study procedure Possible allergy ingredient study medication Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Atopic eczema</keyword>
	<keyword>Topical corticosteroid</keyword>
</DOC>